Nyxoah U.S. study meets primary safety and efficacy endpoints
Nyxoah said its U.S. obstructive sleep apnea (OSA) device met all primary safety and efficacy endpoints in patients with complete concentric collapse (CCC) of the soft palate. The company is preparing a premarket approval supplement.
Nyxoah said a U.S. study of its obstructive sleep apnea device met all primary safety and efficacy endpoints in patients with complete concentric collapse of the soft palate. The medical technology company said Wednesday it is preparing a premarket approval supplement.